Intensive high-dose chemotherapy (HDC) followed by allogeneic (SCT) or autologous (ASCT) stem cell transplantation is increasingly being used as a potentially curative treatment for various cancers and hematological diseases. This treatment has decreased the mortality rates, although it carries significant physical and psychological side effects. 1, 2 There are several reports of medical late effects after HDC and transplantation, with or without total body irradiation (TBI). [3] [4] [5] [6] [7] [8] Subjective late effects are less well documented, although increasing attention is being devoted to health-related quality of life (HRQOL) in relation to cancer treatment in general. 9 Despite the escalating numbers of long-term survivors and the fact that the first transplants were carried out more than two decades ago, most reports on subjective health status and side effects are still cross-sectional, and if longitudinal rarely go beyond the first 3 months post transplant.
A prospective design with follow-up extending at least the first year post transplant is probably the best method to assess the fluctuations in HRQOL and psychological distress during the course of treatment and periods of rehabilitation.
By extensive literature searches we were able to trace 13 prospective reports on hematological malignancies with follow-up that went beyond 3 months post transplant and had sample sizes exceeding 40 patients (from 52 to 415). [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] None of these encompassed patient reference groups for comparisons, although patient data on HRQOL or health perception were compared with general population scores in three reports. 12, 13, 21 Direct comparisons across studies are difficult due to differences in study end points, study populations (diagnoses and types of transplant), methods of evaluating subjective health and length of follow-up.
Generally speaking, most patients seemed to have reached an acceptable level of functioning during the first year after transplant. Nevertheless, when specifically assessed, some areas were still impaired. The patients mainly reported impaired physical functioning, 12, 21, 23, 24 sexual problems 14, 16 and fatigue. 10, 17, 18, 21 Fatigue is one of the commonest symptoms reported by cancer patients 25 and particularly among Hodgkin's disease survivors (HDSs) receiving conventional chemotherapy. 26, 27 Fatigue is reported as a significant symptom that seems to persist after transplant, and possibly even increases over time. 17, 28 However, we were unable to identify any prospective studies assessing fatigue in a longitudinal follow-up beyond the first year after transplant.
We have previously reported HRQOL measured by European Organization for Treatment and Research of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). 24 Compared to lymphoma patients treated with ASCT, leukemia patients treated with SCT had better HRQOL on most scales and items both before transplant and at 1 year after transplant. Because few studies have followed patients for more than the first year, we extended our original follow-up to all patients who were alive at least 3 years beyond transplant.
Our underlying hypotheses were based on clinical experience and our previous work. 4, 23, 24, 27, 29 When contrasting patients with the general population, we expected to find impairment in HRQOL, as assessed by the EORTC QLQ-C30 and the Fatigue Questionnaire (FQ), on some or all of the following scales: role, social and cognitive function, global QOL, dyspnea and fatigue. Differences across patient groups were expected in the direction of impairment in the lymphoma transplant group (ASCT) at the last assessment. We did not expect significant differences in psychological distress across groups, nor compared with population scores.
There were three main objectives with this report:
1. To describe the fluctuations in HRQOL, fatigue, anxiety and depression in patients with hematological or lymphoid malignancies treated with stem cell transplantation or standard chemotherapy, over a period of 3 years or more since start of treatment. 2. To compare scores on role, social and cognitive function, global QOL, dyspnea and fatigue of the EORTC QLQ-C30 and FQ across groups after 3 years from start of treatment. 3. To compare patients' scores on these dimensions with age-and gender-adjusted population values at this time.
Materials and methods

Patients
The recruitment of patients and the participation rates are described in detail elsewhere. 24, 30 Initially, 76 SCT, 85 ASCT and 161 CT patients were approached. Of these, 61, 69 and 118 patients respectively completed the baseline questionnaires at the time of study entry. Over the years of follow-up, 16 SCT, 14 ASCT and 20 CT patients died, while seven, 13 and 38 patients respectively withdrew (10 CT patients received ASCT due to relapse after the first year). If a questionnaire was missing but the patients stated that they were willing to continue in the study, they were not excluded. Those who failed to fill in two consecutive questionnaires even after a reminder, or who stated on the provided coupons that they wished to withdraw, were omitted from further analyses.
The HRQOL, anxiety and depression were measured prospectively by the EORTC QLQ-C30 31 and the Hospital Anxiety and Depression Scale (HADS). 32 The transplant patients received questionnaires twice pre-transplant and then seven times during the following 12 months. The reference group (CT group) received seven questionnaires in the first year after start of chemotherapy.
For practical reasons, the evaluation beyond the third anniversary since transplant was performed as a crosssectional assessment. The EORTC QLQ-C30, 31 the HADS 32 and the FQ [33] [34] [35] were mailed to the 141 eligible patients (38 SCT, 42 ASCT and 61 CT) of whom 128 responded. The response rates at the last assessment were 92, 95 and 87%, respectively.
Questionnaires
The EORTC QLQ-C30
The EORTC QLQ-C30, version 1.0, was employed throughout the follow-up. 31 It incorporates five functional scales (physical, role, emotional, social and cognitive), and one scale assessing overall health/global QOL. Higher scores on these scales signify better functioning. Three symptom scales measure fatigue, pain and nausea and vomiting, while six single items assess symptoms commonly reported by cancer patients (dyspnea, sleep disturbances, appetite loss, diarrhea, constipation and financial impact). Higher scores on the symptom scales and single items represent greater symptomatology or impairments. Mean scale and item scores were transformed to a 0-100 scale as described in the EORTC Scoring Manual. 36 The Hospital Anxiety and Depression Scale
The HADS 32 encompasses 14 questions, each with four categorical answers ranging from zero to three. There are two scales, one for anxiety (seven questions) and one for depression (seven questions). The total score for each scale, derived by simple addition, indicates the extent of anxiety and depression, with higher scores meaning more distress. It has been successfully validated against other psychiatric scales 37, 38 and is recommended for use as a screening instrument for in-and outpatients. 39, 40 Fatigue questionnaire
The FQ [33] [34] [35] asks about fatigue symptoms experienced during the last month compared with how the subjects felt when they were last well. It consists of 11 questions that were generated to reflect physical and mental fatigue. 33 The FQ was originally validated in primary care, has demonstrated good face and discriminant validity 33 and good and stable properties across populations. 27, [33] [34] [35] 41 Physical fatigue (PF) corresponds to the subjective feeling of being exhausted and lacking energy, while mental fatigue (MF) is about the subjective feeling of being mentally exhausted, encompassing items on concentration, memory and speech. The seven items on PF and the four items on MF all have four response categories (0: 'better than usual'; 1: 'no more than usual'; 2:'worse than usual'; and 3: 'much worse than usual'). Thus, higher scores imply more fatigue and the sum score of all 11 items is designated total fatigue (TF). 33 The FQ contains two additional items about the duration and extent of fatigue. The 11 items on physical and mental fatigue is also scored on a dichotomized scale (0, 0, 1, 1) for the identification of chronic fatigue. 33 By comparing the FQ to the fatigue question in the Revised Clinical Interview Schedule (CIS-R), a relative operating characteristics analysis suggested that a cutoff point of 4 or higher on the dichotomized scale would be the optimum cutoff for a 'case definition'. As for most such definitions in medicine however, the cutoff point should be regarded as arbitrary. We have preferred to use the concept chronic fatigue instead of fatigue caseness. In addition to a dichotomized score of 4 or higher, chronic fatigue also implies a duration of 6 months or longer. This is in accordance with the working definition of the Chronic Fatigue Syndrome, and transient fatigue is thereby excluded. The working definition of the chronic fatigue syndrome also includes various other symptoms that were not assessed in the present study. The FQ was not translated into Norwegian at study start, but we decided to introduce the Norwegian version for the final assessment because it has higher sensitivity and specificity for assessment of fatigue than the EORTC QLQ-C30. The decision to add detailed assessment of fatigue was based on our clinical experience and recent reports of persisting and even increasing levels of fatigue with the passage of time since transplant. 17, 18, 28 
Population values
Patients' scores on the EORTC QLQ-C30, the FQ and the HADS were compared against reference values from three Norwegian general population surveys. 29, 41, 42 Two of the samples 29, 41 came from random draws of all inhabitants by The Office of the National Register and were representative of the adult Norwegian population. The EORTC QLQ-C30 and the FQ were mailed to 3000 and 3500 adult Norwegian citizens, yielding response rates of 68 and 67%, respectively. The population data on the HADS were from a large health survey including all inhabitants aged 20-89 years in Nord-Trndelag county (the Nord-Trndelag Health Study) that had a response rate of 71%. 42 The 52 000 respondents with complete HADS scales formed the basis for analyses. The psychometric properties of the Norwegian version of the HADS were considered good and stable across different population subgroups.
Comparisons between patient data and population values were made allowing for age and gender, because these variables have been shown to impact on the differences between groups. 43 Expected mean scores for the patient groups were computed from age and gender equivalent reference values, as previously described. 43 
Statistical analyses
Standard descriptive statistics were employed to describe the distribution of the EORTC, HADS and FQ scores at all assessments. w 2 tests (nominal categorical variables), Wilcoxon's test (two-tailed) for independent samples or one-way ANOVA, with Tukey's test for post hoc comparisons were used to test for differences in medical and demographic characteristics and for the variables related to the specified study hypotheses, as appropriate. We present the data as graphic displays with figures and confidence bars describing the temporal patterns; this portrays the clinically relevant patterns and novel information from our study in an easily assimilable manner, and indicates the precision of the estimates. Statistical approaches such as three-group ANOVA or MANOVA would have required the specification of models to represent temporal patterns that, based on our clinical experience and previous work, we did not expect to be consistent over time; in our opinion, these more complex methods would add little extra information. A conservative approach with a 0.01 level of statistical significance was used with all tests to reduce the impact of multiple testing.
Differences greater than 10 on the transformed EORTC scales (range 0-100) were regarded as clinically significant in this study. 24, 43, 44 The 95% confidence intervals were marked on the figures, to provide more information about the estimates of the true values regarding the within-and between-groups mean differences.
To avoid omitting patients with partially incomplete data, mean imputation was used for scale scores when patients completed at least 50% of the scale (as recommended by the EORTC Manual). 36 Figures and analyses were produced by Excel, version 5.1, 45 STATA release 7.0 46 and SPSS statistical software version 10.0. 47 The Regional Committee for Medical Research Ethics, Health region I, Norway and the institutional review boards at the NRH approved the study.
Results
Demographic and medical characteristics
No significant differences across groups were found with respect to socio-demographic variables ( Table 1 ). The patient sample was all Caucasian, well-educated (60% with a lower level college/university degree) and the majority was married (65-75% across groups). Most SCT patients (N ¼ 31, 51% at baseline and 23, 66% after 3-5 years) suffered from chronic myelogenous leukemia (CML). The most common diagnosis in the ASCT and CT groups at baseline was high-grade non-Hodgkin's lymphoma (H-NHL) constituting 62 and 57%, respectively. At the last assessment, the majority of the ASCT group consisted of patients with H-NHL (N ¼ 24, 59%), while the most common diagnosis in the CT group was Hodgkin's disease (N ¼ 28, 52%) ( Table 1) .
A total of 72% of the SCT patients were in first complete remission of acute leukemia or in a first chronic phase of CML at the time of transplant, compared to 15% in the ASCT group (Po0.0001). All ASCT patients had received combination chemotherapy, as did the 30 (49%) SCT patients suffering from AML or ALL. A total of 30 SCT patients with CML had been treated with hydroxyurea. 24 One SCT patient had been treated with additional radiotherapy against the central nervous system as part of the primary treatment, but 19 (28%) of the ASCT patients were given various radiation fields (Po0.0001). A total of 45 of the ASCT patients (65%) had received TBI of 1.3 Gy Â 10, compared to one SCT patient (Po0.0001). Of the SCT patients, 43% (N ¼ 26) suffered from acute graft-versus-host disease (GVHD) during hospitalization, while 27% had chronic GVHD at the 1-year examination, two with extensive disease. The patients received cyclosporine A from day À1, and low-dose methotrexate on days þ 1, þ 3, þ 6 and þ 11. Cyclosporine was tapered after 3-6 months and most patients were off this drug within 1 year.
All CT patients had been treated with conventional chemotherapy according to the underlying disease. 24 In all, 77% of the SCT patients, 78% in the ASCT group and 88% of the CT patients were working at a paid job or studying at the assessment after 3 years or more. The major reason for being on sick leave or disability pension was related to the cancer disease or treatment in all three groups: SCT, 9/13 (67%); ASCT, 100%; and CT, 6/8 (75%).
Changes from baseline HRQOL scores
There were clinically significant differences across the two transplant groups at baseline in the direction of better HRQOL in the SCT group on nine scales and items (differing from 12 to 19 points; Table 2 ). The differences in global QOL (76 (CI 70-81) vs 58 (CI 52-64)) and fatigue (26 (CI 21-31) vs 45 (CI 39-51)) were most pronounced. Figure 1a and b delineates the mean changes from baseline values for each group at each assessment on the selected EORTC scales and items. A substantial increase in symptoms and reduction in functional levels occurred between baseline and the assessment 2 weeks post transplant (SCT/ASCT), when most patients were still in the isolation unit. The SCT group reported great impairments in all the functional scales and high levels of symptoms. Gradual improvements in function and symptom scores were observed after the 2-week post transplant assessment, before stabilizing at baseline levels after 4-8 months. The SCT group had function and symptom scores similar to baseline levels at the 1-year assessment, but reported a clinically significant improvement in social function from 62 (CI 54-71) to 75 (CI 67-83) and role function from 76 (CI 68-85) to 88 (CI 80-96) (Figure 1a and b).
The ASCT patients generally reported smaller changes from baseline scores during the first year compared with the SCT group, and showed a more rapid return to baseline values. At 2 months post transplant, the social and role function scores were similar to or above the baseline scores, as was global QOL after 4 months. Most symptom scores and single items had returned to baseline levels after 2 months, except for dyspnea and fatigue. A continuous improvement was seen toward the 1-year assessment (Figure 1a and b) . The most pronounced clinically significant improvements within the first year were found with role function 61 (CI 53-69) vs 82 (74-90) and social function 55 (CI 48-62) vs 78 (CI 70-84). No significant changes in function scores from baseline levels were observed in the CT group within the first 8 months. A negative change in global quality of life was observed after 4-6 months, before scores stabilized at a level significantly above baseline (Figure 1a and b). The greatest difference was observed with social function, improving by 19 from 61 (CI 55-66) to 80 (CI 78-87).
HRQOL beyond the first year
When the patients were at least 3 years beyond transplant, few significant differences were found compared with the results after 1 year (data not tabulated). The timing of the final assessments ranged from 3 to 5 years post transplant, but no significant differences were found for any of the outcome measures when comparing patients evaluated before and after the median follow-up time.
The SCT group reported a clinically significant improvement from at 1 year with global QOL differing by 12 and social function by 13. Role function, however, declined significantly toward the mean baseline values. The greatest differences across transplant groups in the direction of more impairment in the ASCT group were found with dyspnea (P ¼ 0.003) and role function (Po0.0001) ( Figure  1a and b) . Clinically significant differences were found with fatigue, cognitive and social function and global QOL, differing by 15, 15, 14 and 13 respectively (P ¼ NS, data not tabulated).
The ASCT patients reported similar values at both 1 year and the last assessment. However, role function declined by 18 points, to baseline levels (Figure 1a and b) . Relative to the CT group, cognitive, role and social function and global QOL were significantly impaired and there was more dyspnea (P-values o0.01; Figure 1a and b; data not tabulated).
The CT patients reported few changes beyond the first year. The most pronounced difference was global QOL, which rose from 73 (CI 67-78) after 1 year to 82 (CI 78-87) at the last assessment (Figure 1a ; data not tabulated).
Compliers vs non-compliers
Overall, there were no distinct differences when comparing the baseline mean values between the 128 patients who completed the entire study period, compared with the scores of the 120 patients who did not comply. There was a 
Comparisons with the general population
At 3-5 years after start of treatment, most patients reported an HRQOL comparable to the age-and gender-adjusted population scores (Table 2) . However, role function was reduced in all groups (Po0.001). The ASCT patients also reported poorer cognitive and social function (Po0.001), and significantly more dyspnea (Po0.001).
Anxiety and depression
No major group differences were found for anxiety and depression at baseline or during follow-up (data not tabulated). The level of anxiety decreased during the first 8 months post treatment 30 and then remained stable until 3 years or more after transplant/start of treatment. No differences between groups were observed. Only minor fluctuations were observed in the CT group. 30 There were no statistically significant differences in anxiety (mean scores (95% CI): 
Fatigue
No statistically significant differences in physical, mental or total fatigue were found across groups at the last assessment (Table 3) , although more ASCT patients (11/ 40, 28%) reported chronic fatigue compared with the SCT group (4/35 patients, 11%) and the CT group (9/44, 20%), but this failed to reach statistical significance (P ¼ 0.08).
All patients reported more physical, mental and total fatigue relative to the general population (P-values o0.01-0.001), while more chronic fatigue (28 vs 9%, w 2 3.4, Po0.001) was found in the ASCT group compared with general population (Table 3) .
Discussion
This prospective study evaluates the changes in the HRQOL of patients with hematological and lymphoid malignancies treated with stem cell transplantation or standard chemotherapy, with a follow-up of more than 3 years.
The overall finding was that most patients reported a good level of HRQOL as assessed by the EORTC QLQ-C30, with the majority being back to work or studies within the first year. This is consistent with other prospective reports. 13, 14, 17, 18, 21, 24 However, when comparing patient data with age-and gender-standardized values from the general population, there was significant impairment in all groups, even beyond the third anniversary of follow-up. This was particularly related to role function on the EORTC QLQ-C30.
We suggest that the elevated levels of fatigue deserve special attention. The three aspects of fatigue (physical, mental and total), as well as chronic fatigue in the ASCT group assessed by the FQ, were significantly more pronounced in all patients compared with population values. Impaired role function was particularly associated with ability to work in version 1.0 of the EORTC QLQ-C30, and high levels of fatigue imply that returning to work might be problematic, despite reports from the majority of patients that they had resumed these activities. Problems in this area are consistent with other prospective studies where returning to normal has been operationalized as resumption of professional or private roles. 10, 17, 18, 21 Patient and population fatigue scores were similar for the EORTC QLQ-C30, but more sensitive tools such as the FQ should be used in preference to general HRQOL instruments. Fatigue has been shown to be a predictor for poor neuropsychological performance post transplant in a recent cross-sectional study employing comprehensive neuropsychological tests. 48 It has been suggested that it might increase with the passage of time, particularly when combination chemotherapy is administered for malignant lymphomas. 27 We found relatively minor fluctuations in anxiety and depression as expected, based on our previous report. 30 Anxiety and/or depression have been reported to be elevated in up to 40% of patients pre-transplant in prospective studies employing various questionnaires, [19] [20] [21] and slightly higher in prospective studies using the DSM-IV criteria, 20, 49, 50 gradually declining during the first year. 15, 18, 19, 21, 30 No such differences were found when Table 3 Fatigue 3 years or more after transplant or start of chemotherapy comparing our data on the widely used HADS questionnaire with the age-and gender-adjusted values from a large population survey (45000 people). This might indicate that psychological distress is less pronounced after intensive, curative and successful treatment relative to the general prevalence of these problems. However, the relationship between anxiety/depression and fatigue on the one hand and the demanding psychological stressors related to the intensive treatment and the long-term side effects that many of these patients are confronted with remains uncertain. The surprisingly low levels of anxiety and depression might suggest that the psychological support that was offered during treatment and follow-up was perceived as adequate by the patients. 51 In this descriptive study, we did not control for variables such as coping resources and social support that are shown to impact on quality of life and reintegration after transplantation. 15, 19, 21, 22 Thus, we cannot rule out that there might be an association between these variables and fatigue in particular, an issue that warrants further investigation.
The distinct baseline differences across the two transplant groups in the direction of better HRQOL in the SCT group persisted and became more pronounced for some dimensions at the last assessment. The ASCT group reported more impairment relative to the general population (dyspnea, cognitive, role, social function, global QOL) and more dyspnea and lower role function compared with the SCT group, even beyond the third anniversary post transplant. It should be kept in mind, though, that the baseline levels did not necessarily reflect the optimal HRQOL, particularly for the ASCT patients. The significant discrepancies relative to the general population substantiate this. On the other hand, the general population does not have a perfect HRQOL, if any such exists, hence this should not be the ultimate goal for treatment.
Thus it is noteworthy that the changes from baseline scores were different for the two transplant groups, in the direction of larger reductions in functions and substantially more symptomatology in the SCT group. The greatest impairment for both groups occurred, as expected, around and shortly after transplant, while the improvement and stabilizing of scores back to baseline levels occurred a little sooner in the ASCT group, after 2-4 months, than in the SCT group (after 4-6 months), consistent with the findings from Lee et al. 17 We believe that this is related to the different etiology of lymphoma vs leukemia, and above all to the pre-transplant treatment history. The majority of the SCT patients had a level of functioning pre-transplant that was directly comparable to that of the population in general. Significantly more ASCT patients received transplants in the advanced stages of disease, after substantially more chemo-and/or radiotherapy. These important clinical factors were substantiated with the elevated levels of dyspnea (mediastinal/mantle fields) as well as the significantly higher percentage of chronic fatigue in the ASCT group relative to the population in general. Thus, we do not believe that the high-dose chemotherapy and the transplant itself are the most influential determinants for post transplant development. Similarly, the slightly higher pain score in the ASCT group (20 vs SCT 11 and CT 9) may be related to the more frequent use of radiotherapy in this group, that is, mantle field irradiation to Hodgkin's lymphoma patients. 52 In one of our previous reports, baseline HRQOL and transplant group (SCT vs ASCT) were predictive of HRQOL after 1 year, but the direct clinical values of such predictions remain uncertain. That is why we, in line with others, 17 have chosen not to investigate possible baseline or transplant characteristics as predictors for selected outcomes at the last assessment. Furthermore, few significant differences were found when comparing baseline scores of compliers and non-compliers in this sample.
We cannot rule out that the differences in HRQOL might have been pronounced with another composition of the transplant groups regarding stage of disease at transplant. However, all patients were recruited on a consecutive basis and treated according to standard protocols and the different indications for when to perform the transplant for leukemia and lymphomas most certainly influenced the post transplant trajectory. Most studies report results from heterogeneous samples with respect to diagnoses and indications for transplant. We strongly advocate the need for subgroup analyses. This yields detailed knowledge about specific groups of patients and will enhance the generalizability of the results provided that there is an adequate number of patients to perform meaningful comparisons and statistical analyses, an inherent part of clinical research. Sample sizes should be large enough to allow for the inevitable attrition due to death and relapse during the follow-up in transplant studies. Thus most studies report seriously declining sample sizes over time, often resulting in less than 50 patients in total after the first year post transplant. 11, 13, 14, 18, 19, 21 Our study reported on all patients initially included, although patient attrition resulted in a different denominator at the various assessments. This gave valuable information about all patients along the trajectory of rehabilitation, and reduces the possible 'healthy bias' that might occur in prospective studies on HRQOL. The mortality was slightly higher in the SCT group than in the ASCT and CT groups (16/61: 26% vs 14/69: 20% vs 20/ 118: 17%). While we found few significant baseline differences between compliers and non-compliers to substantiate our clinical impression, we believe that the most well-functioning SCT and ASCT patients completed the questionnaires, while the opposite was found in the CT group: Several of these patients dropping out during follow-up stated upon request that they felt well, and did not want to take part in the study any more. Thus discrepancies between the CT group and the transplant patients might be larger than demonstrated here. The more frequent and intense follow-up of the transplant patients might be a plausible explanation for the lower dropout compared to standard care patients. This is substantiated with the transplant patients requesting very little help when specifically asked on the CARES questionnaire. 51 Relatively minor changes in scores were found after the first year, and in accordance with this the timing of the final assessment (between 3 and 5 years) did not seem to have any effect. This is consistent with other studies, 17, 18, 28 which found that little substantial improvement occurred after the first year post transplant. However, studies that assessed patients after 3 or more years have reported improvements, indicating that time since transplant may be an important variable for HRQOL. 13, [53] [54] [55] A possible explanation for this could be that some side effects from chemotherapy, such as vinca-alkaloid-induced neurotoxicity, may resolve beyond the first years.
There are reports comparing certain aspects of QOL such as health perception 13 and anxiety/depression 12 with population values, but we failed to find prospective reports that made age-and gender-adjusted comparisons with population values for the majority of the QOL dimensions. The interpretation and validity of such comparisons must be kept in mind, however. It could be that the patients discount problems not related to their disease, but these problems might be regarded as more important, and reported, by people in population surveys. If so, the HRQOL scores of the patients might appear better than expected. Although group values are not directly applicable to an individual patient, 'normative' population data provide a useful baseline for the counselling of patients.
The major strengths of this study are the long-term prospective follow-up, the relatively large sample size, the use of well-validated questionnaires, and the comparisons with age-and gender-standardized reference data. The differences across transplant groups accentuate the importance of performing prospective studies, in order to improve care.
These results have major implications for those oncologists and hematologists who treat these three groups of patients. The differences across transplant groups, the different development during the first year of treatment, the impaired role function and the elevated levels of fatigue should have direct clinical implications in optimizing care and information. The importance of assessing HRQOL in patients undergoing stem cell transplantation was emphasized in two recent publications. One showed that physicians tended to overestimate the quality of life in their patients, 28 while the concordance between physicians' and patients' estimates regarding the success of transplant with respect to mortality and morbidity is largely dependent on the information given (or withheld). 56 We strongly recommend regular follow-up of the patients beyond the first 3 years post transplant. Special emphasis should be directed toward functional status and fatigue, particularly in lymphoma patients who have received extensive treatment prior to transplant. The use of knowledge-based information should improve the counselling and routines for follow-up, including medical and psychological support. Evaluation and enhancement of the patients' own resources and their perceived and actual social support might facilitate the transition between intensive hospital care and the home environment, toward rehabilitation and resumption of prior roles.
